Skip to main content
Top
Published in: Tumor Biology 5/2014

01-05-2014 | Research Article

Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells

Authors: Ahmed H. Mekkawy, Mohammad H. Pourgholami, David L. Morris

Published in: Tumor Biology | Issue 5/2014

Login to get access

Abstract

Breast cancer is the most common cancer and the leading cause of cancer death in women worldwide. Expression of human Sprouty1 (hSpry1) gene is downregulated in most breast cancer patients, implicating it as an important tumor suppressor gene. So, we hypothesized that overexpression of hSpry1 gene may suppress breast cancer cell growth, migration, and invasion. Here, we demonstrate that in breast cancer cell lines, MDA-MB-231 and T47D, transfection-induced overexpression of hSpry1 reduced cell population, proliferation, and colony formation in vitro without affecting cell apoptosis. Adhesion molecules act as both positive and negative modulators of cellular migration and invasion. Here, we found that overexpression of hSpry1 enhances the initial establishment events in breast cancer cell adhesion to type IV collagen and vitronectin. Moreover, the overexpression of hSpry1 in the highly invasive MDA-MB-231 breast cancer cells causes a significant reduction in cellular migration and invasion through Matrigel membranes. In addition, we showed that hSpry1 overexpression prevents VEGF secretion. VEGF is essential for primary tumor growth, migration, and invasion. Thus, our study provides a novel mechanism of tumor suppression activity of hSpry1.
Literature
1.
go back to reference Hacohen N et al. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998;92(2):253–63.CrossRefPubMed Hacohen N et al. sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell. 1998;92(2):253–63.CrossRefPubMed
2.
go back to reference Tefft JD et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol. 1999;9:219–22.CrossRefPubMed Tefft JD et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol. 1999;9:219–22.CrossRefPubMed
3.
go back to reference Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell. 1999;96(5):655–65.CrossRefPubMed Casci T, Vinos J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell. 1999;96(5):655–65.CrossRefPubMed
4.
go back to reference Sasaki A et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol. 2003;5(5):427–32.CrossRefPubMed Sasaki A et al. Mammalian Sprouty4 suppresses Ras-independent ERK activation by binding to Raf1. Nat Cell Biol. 2003;5(5):427–32.CrossRefPubMed
5.
go back to reference Rubin C et al. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol. 2003;13(4):297–307.CrossRefPubMed Rubin C et al. Sprouty fine-tunes EGF signaling through interlinked positive and negative feedback loops. Curr Biol. 2003;13(4):297–307.CrossRefPubMed
6.
go back to reference Impagnatiello MA et al. Mammalian sprouty-1 and −2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol. 2001;152(5):1087–98.CrossRefPubMedPubMedCentral Impagnatiello MA et al. Mammalian sprouty-1 and −2 are membrane-anchored phosphoprotein inhibitors of growth factor signaling in endothelial cells. J Cell Biol. 2001;152(5):1087–98.CrossRefPubMedPubMedCentral
7.
go back to reference Gross I et al. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem. 2001;276(49):46460–8.CrossRefPubMed Gross I et al. Mammalian sprouty proteins inhibit cell growth and differentiation by preventing ras activation. J Biol Chem. 2001;276(49):46460–8.CrossRefPubMed
8.
go back to reference Lo TL et al. The Ras/Mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, Sprouty 1 and Sprouty 2 are deregulated in breast cancer. Cancer Res. 2004;64:6127–36.CrossRefPubMed Lo TL et al. The Ras/Mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, Sprouty 1 and Sprouty 2 are deregulated in breast cancer. Cancer Res. 2004;64:6127–36.CrossRefPubMed
9.
go back to reference Kwabi-Addo B et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 2004;64:4728–35.CrossRefPubMed Kwabi-Addo B et al. The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. Cancer Res. 2004;64:4728–35.CrossRefPubMed
10.
go back to reference Sirivatanauksorn Y et al. Differential expression of sprouty genes in hepatocellular carcinoma. J Surg Oncol. 2012;105(3):273–6.CrossRefPubMed Sirivatanauksorn Y et al. Differential expression of sprouty genes in hepatocellular carcinoma. J Surg Oncol. 2012;105(3):273–6.CrossRefPubMed
11.
go back to reference Fong CW et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006;66(4):2048–58.CrossRefPubMed Fong CW et al. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res. 2006;66(4):2048–58.CrossRefPubMed
12.
go back to reference Mekkawy AH et al. Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun. 2010;399(4):738–43.CrossRefPubMed Mekkawy AH et al. Novel protein interactors of urokinase-type plasminogen activator receptor. Biochem Biophys Res Commun. 2010;399(4):738–43.CrossRefPubMed
13.
go back to reference Mekkawy AH, Morris DL. Human Sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion. ISRN Biochem. 2013;2013:7.CrossRef Mekkawy AH, Morris DL. Human Sprouty1 suppresses urokinase receptor-stimulated cell migration and invasion. ISRN Biochem. 2013;2013:7.CrossRef
15.
go back to reference Pourgholami MH et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012;125(2):433–40.CrossRefPubMed Pourgholami MH et al. Minocycline inhibits growth of epithelial ovarian cancer. Gynecol Oncol. 2012;125(2):433–40.CrossRefPubMed
16.
go back to reference Mekkawy AH, Morris DL, Pourgholami MH. HAX1 augments cell proliferation, migration, adhesion, and invasion induced by urokinase-type plasminogen activator receptor. J Oncol. 2012;2012:950749.CrossRefPubMedPubMedCentral Mekkawy AH, Morris DL, Pourgholami MH. HAX1 augments cell proliferation, migration, adhesion, and invasion induced by urokinase-type plasminogen activator receptor. J Oncol. 2012;2012:950749.CrossRefPubMedPubMedCentral
17.
go back to reference McClay, D.R. and P.L. Hertzler, Quantitative measurement of cell adhesion using centrifugal force. Curr Protoc Cell Biol, 2001. Chapter 9: p. Unit 9 2. McClay, D.R. and P.L. Hertzler, Quantitative measurement of cell adhesion using centrifugal force. Curr Protoc Cell Biol, 2001. Chapter 9: p. Unit 9 2.
18.
go back to reference Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12 Suppl 1:S70–80.CrossRefPubMed Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J. 2006;12 Suppl 1:S70–80.CrossRefPubMed
19.
go back to reference Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell. 2000;103(1):13–5.CrossRefPubMed Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell. 2000;103(1):13–5.CrossRefPubMed
20.
go back to reference Ozaki K et al. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci. 2005;118(Pt 24):5861–71.CrossRefPubMed Ozaki K et al. Efficient suppression of FGF-2-induced ERK activation by the cooperative interaction among mammalian Sprouty isoforms. J Cell Sci. 2005;118(Pt 24):5861–71.CrossRefPubMed
22.
go back to reference Gross I et al. The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. J Biol Chem. 2003;278(42):41420–30.CrossRefPubMed Gross I et al. The receptor tyrosine kinase regulator Sprouty1 is a target of the tumor suppressor WT1 and important for kidney development. J Biol Chem. 2003;278(42):41420–30.CrossRefPubMed
23.
go back to reference Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–2.CrossRefPubMed Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–2.CrossRefPubMed
24.
go back to reference Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol. 2011;716:157–68.CrossRefPubMed Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol. 2011;716:157–68.CrossRefPubMed
25.
go back to reference Aumailley M, Timpl R. Attachment of cells to basement membrane collagen type IV. J Cell Biol. 1986;103(4):1569–75.CrossRefPubMed Aumailley M, Timpl R. Attachment of cells to basement membrane collagen type IV. J Cell Biol. 1986;103(4):1569–75.CrossRefPubMed
26.
go back to reference Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5(5):864–8.CrossRefPubMed Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr Opin Cell Biol. 1993;5(5):864–8.CrossRefPubMed
28.
go back to reference Hurt EM et al. Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells. 2010;28(3):390–8.PubMedPubMedCentral Hurt EM et al. Identification of vitronectin as an extrinsic inducer of cancer stem cell differentiation and tumor formation. Stem Cells. 2010;28(3):390–8.PubMedPubMedCentral
29.
go back to reference De Bock CE et al. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. Int J Oncol. 2010;36(5):1155–63.PubMed De Bock CE et al. Interaction between urokinase receptor and heat shock protein MRJ enhances cell adhesion. Int J Oncol. 2010;36(5):1155–63.PubMed
30.
go back to reference Akbulut, S., et al., Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C. Mol Biol Cell, 2010 Akbulut, S., et al., Sprouty proteins inhibit receptor-mediated activation of phosphatidylinositol-specific phospholipase C. Mol Biol Cell, 2010
31.
32.
go back to reference Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.CrossRefPubMed Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer. 2002;2(10):795–803.CrossRefPubMed
33.
go back to reference Tang L et al. Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. Food Chem Toxicol. 2013;56:204–13.CrossRefPubMed Tang L et al. Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells. Food Chem Toxicol. 2013;56:204–13.CrossRefPubMed
34.
35.
go back to reference Salva E et al. Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo. Nucleic Acid Ther. 2012;22(1):40–8.PubMed Salva E et al. Local delivery of chitosan/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo. Nucleic Acid Ther. 2012;22(1):40–8.PubMed
36.
Metadata
Title
Human Sprouty1 suppresses growth, migration, and invasion in human breast cancer cells
Authors
Ahmed H. Mekkawy
Mohammad H. Pourgholami
David L. Morris
Publication date
01-05-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1665-y

Other articles of this Issue 5/2014

Tumor Biology 5/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine